The drivers of health care costs, federal spending, consumer spending, and industry consolidation.
During this briefing, panelists explained the mechanisms of biologic drugs, explore the impact of current regulations on the uptake of biosimilars, and discuss considerations for the biosimilars market in the United States.
The audience will come away with a better understanding of the origins of the rebate system, the actors responsible for negotiation, and the impact of rebates on prescription drug prices.
This congressional briefing explored the differences between “price” and “cost” in our current system and the potential policy options that address these discrepancies.
The conversation on health care costs in America is decades old, yet progress has been elusive. Terms like sustainability, affordability, and value are set forward as goals, but perspectives on how to achieve them vary widely. Speakers and panelists will provide insights on current and projected health care cost trends, what different stakeholders hope to achieve, and new approaches to consider.
This is the first webinar, part of the Beyond the Beltway: Health Webinars for Journalists series, focused on the implications and tradeoffs of the recent trends in the health care market. Panelists helped define the basics of market concentration and competition, how experts measure the effects on different areas of the market, and how regulators approach assessing partnership proposals.
This briefing provided an update on the overall state of play with payment reform, and the effort to move away from fee for service and toward value-based payment. Panelists discussed the interplay between the public and private sectors, and, given likely future directions for the CMS Center for Medicare and Medicaid Innovation, highlighted areas where the private sector may be best positioned to lead. Panelists shared what this means for future policy options and needs.
This Alliance for Health Policy briefing discussed current issues in prescription drug affordability and innovation, focusing on potential policy and private-sector approaches to this complex issue.
Coordinated Care and Beyond: The Future of Integrated Care for Complex Chronic Conditions: What’s Working, What’s Not?
This is the final of three panels from our Future of Chronic Care Summit.
This is the second of three panels from our Future of Chronic Care Summit.
This is the first of three panels from our Future of Chronic Care Summit.
This half-day summit examined how to improve care for patients with complex, chronic conditions.
This briefing featured presentations by our experts highlighting the trends in Medicare regarding prescription drug pricing, and panelists discussed an array of policy options to align drug prices with value through alternative payment models.
Medicaid is testing numerous new alternative payment and delivery system models to enhance the coordination of the health care services provided to millions of low-income Americans. This briefing examined the range of Medicaid’s efforts to improve care and promote value, including integrating health with non-clinical and behavioral services, creating managed care organizations, and instituting regional care collaborative organizations. Our panel also addressed Medicaid’s role in managing emerging issues such as the opioid epidemic and the spread of the Zika virus.
Health systems have applied many innovative new strategies for improving quality and reducing costs when it comes to care for high-need, high-cost patients, who typically have multiple chronic conditions. Which of these innovations show promise, and what can we learn from them?
The Centers for Medicare & Medicaid Services (CMS) recently closed the public comment period for its proposed rule to implement the Medicare Access and CHIP Reauthorization Act (MACRA). This means that Medicare will soon change its payment system for physicians, and there could be broad implications for physicians, health systems, health plans, consumers and others.
The Centers for Medicare & Medicaid Services (CMS) closed on June 27 the public comment period for its proposed rule implementing the Medicare Access and CHIP Reauthorization Act (MACRA). This means that Medicare will soon change its payment system to emphasize value over volume, and physicians caring for Medicare patients will need to make decisions about how to adapt their practices to the new incentives.
With biosimilar biological products moving from the lab to the marketplace, key policy and regulatory questions are being actively debated, with important implications for industry, patients, and the health care system.
Recent pharmaceutical innovations offer unprecedented possibilities for curing, treating, or preventing a range of diseases. However, patients, providers and payers alike have raised concerns about the affordability and sustainability of these drugs. As a response to price increases of both single-source and generic drugs, some stakeholders are calling for a move towards basing payments on value, and some payers and pharmaceutical manufacturers are exploring ways to base payments on outcomes. However, many challenges remain.
Medicare is testing new ways to pay for medical services, emphasizing value rather than volume, and evidence is beginning to build about successes and challenges. This briefing will examine what we know so far about the basic models, savings, quality, the impact on patients and the prospects for replication.
A governor met with reporters Friday, February 19 to discuss the latest health care innovations and changes they are pursuing or implementing. Gov. Asa Hutchinson, R-Ark., discussed his experience with the state’s program to move newly eligible Medicaid beneficiaries to qualified health plans, and his intentions for changes moving forward.
A top Federal Trade Commission official, along with key experts, met with reporters Dec. 15 to discuss the recent surge in health care consolidation; the driving forces behind this trend; and the implications for policymakers and enforcers.